Your Findings Will Be Heard Loud & Clear
SCAI's late-breaking clinical trials have been prominently featured in mainstream and trade media including The Wall Street Journal, USA Today, The Los Angeles Times and The Washington Post.

The Right Audience for Your Research
SCAI Scientific Sessions offer a collegial environment for education, research and collaboration among interventional cardiologists from around the world.

SCAI needs your help in identifying those invasive/interventional cardiologists who have made significant contributions to SCAI and helped spur our specialty's growth. Help SCAI honor those who demonstrate excellence in invasive/interventional cardiology and a commitment to the highest levels of clinical care, innovation, publication and teaching.

During this call, find out how to complete the final reporting period for the legacy Medicare quality reporting programs and transition to the Merit-based Incentive Payment System (MIPS). A question and answer session follows the presentation. Refer to the call detail page for more information.

TCTMDIn STEMI patients with multivessel disease, culprit-vessel PCI followed by staged nonculprit revascularization leads to better outcomes at two years versus complete revascularization at the index PCI or infarct-only PCI, data from a large registry suggests. However, the paper also adds evidence that treatment choice needs to take into account factors such as severity of illness, age and location of the nonculprit vessel.
READ MORE

Cardiovascular BusinessResearchers have identified 26 different predictive biomarker signatures to help determine how well a person is aging.
A new study conducted by researchers at the Boston University Schools of Public Health and Medicine examined how levels of specific biomarkers can be combined to produce patterns to signify how well a person is aging and their risk for future aging-related diseases, including dementia and cardiovascular disease.READ MORE

.

PRODUCT SHOWCASE

TR BAND® - The Clear AdvantageTR Band Radial Compression Device is the #1 preferred and most used hemostasis device on the market. An innovative design that results in unrivaled performance.
Features include:

The Cardiology Advisor Female patients undergoing transcatheter aortic valve replacement (TAVR) procedures experience elevated one-year survival rates versus male patients, according to research published in the Journal of the American College of Cardiology. Dr. Roxana Mehran, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues used data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to compare results among female (49.9 percent of study population) and male (51.1 percent) TAVR patients.
READ MORE

Cardiovascular BusinessStarting this year, a large number of cardiologists treating fee-for-service Medicare patients will participate in programs in which their reimbursement is tied to providing value-based care. It is the continuation of a trend that many leaders in the healthcare industry believe will become the norm.
READ MORE

The Cardiology AdvisorAlthough current U.S. and European guidelines recommend delaying surgery in patients for 6 to 12 months after drug-eluting stent percutaneous coronary intervention (DES-PCI), a new study suggests surgery might be performed earlier without increased risk.
Researchers in Aarhus, Denmark, collected data on 22,590 patients who underwent DES-PCI between 2005 and 2012. A total of 4303 patients were compared with a control group without previous ischemic heart disease who underwent similar surgical procedures.READ MORE